Pushing Rx to help employers ‘Be Well’
Meijer has launched a new, smaller prototype that provides pharmacy with a higher operational profile in a critical market. The format was developed with the Chicago market in mind, but it could be popping up in more locations as Meijer explores the strengths of its operations in more densely populated geographies.
Because the new format considerably cuts back on general merchandise, it is described by the retailer as pharmacy- and grocery-focused. So Meijer is, essentially, counting on the initiatives it has launched in those operations to sell the store to new customers. Of course, Meijer has been among the most eager proponents of providing free antibiotics to establish itself as a family-oriented retailer.
The company’s first smaller-format store had a January launch in the Chicago suburb of Niles, Ill. At 102,000 sq. ft., it comes in at about half the size of a typical Meijer supercenter. A second smaller-format Meijer is preparing to launch in Orland Park, another Chicago suburb. Frank Guglielmi, a Meijer spokesman, said the pharmacy is similarly located to the retailer’s supercenters. “It’s still up on the corner of grocery with health-and-beauty aids,” he said. “And it still has a drive-through.”
Headquarters: Grand Rapids, Mich.2009 sales: $15.1 billion% change vs. 2008: 2.7%No. of stores: 190No. of stores with Rx: 190Avg. store size: 205,000 sq. ft.Rx sales: $453 million% of sales from Rx: 3%Sales per store: $79.5 million
Source: Company reports
Meijer is promoting free antibiotics and prenatal vitamins to help draw customers to its new stores. The retailer added free antibiotics in 2006 and free prenatal vitamins in 2008. The program is widely popular with customers in Michigan, where the company is headquartered, and in the rest of its market area, including Illinois, Ohio, Indiana and Kentucky. “We’re over 5 million free antibiotic prescriptions filled, and over half a million prenatal vitamin scripts filled,” Guglielmi said.
Building on an initiative it launched in 2008, Meijer continues to expand Be Well, a program that offers a range of health-related services through a partnership with 4D Pharmacy Management Systems. Meijer provides employers that contract with 4D the chance to sign up for Be Well for an expanded employee benefits package that includes everyday discounts on private-label vitamins, minerals, supplements and organic food. While it isn’t ready to make any major announcements on Be Well, Guglielmi said the program continues to add companies and remains in growth mode.
Schnucks’ O’Brien to serve on Department of Agriculture advisory committee
ST. LOUIS An executive from Schnuck Markets will serve on an advisory committee of the Department of Agriculture, Schnucks said this week.
Agriculture secretary Tom Vilsack announced that Schnucks VP produce and floral Mike O’Brien would be one of 25 people appointed to a two-year term on the USDA’s Fruit and Vegetable Industry Advisory Committee. O’Brien is also vice chairman of the Produce Marketing Association.
“I am honred to represent Schnuck Markets and the retail produce industry as a member of this committee,” O’Brien said. “I am looking forward to the opportunity to contribute and to make a difference for families across the nation.”
The committee, originally chartered in 2001, advises the secretary of agriculture on industry issues related to fruits and vegetables.
Gilead commences phase 3 trial for single-tablet HIV treatment
FOSTER CITY, Calif. Gilead Sciences has started a late-stage clinical trial of an investigational 4-in-1 treatment for HIV, the drug maker said.
Gilead announced the initiation of a phase 3 trial of its “Quad” HIV drug, a single-tablet treatment that combines elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The study will compare the Quad regimen with the standard of care among adults with HIV-1 who have not taken antiretroviral treatments. The company is also investigating cobicistat as a standalone boosting agent for antiretroviral drugs.
“We are pleased to announce that the Quad phase 3 clinical program is underway,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said. “Efficacy and safety results from the phase 2 study suggest that the Quad may represent an important new option for patients with HIV.”